AIDSWEEKLY Plus; Monday, May 1, 2000
Prepared by AIDS Weekly editors from staff and other reports

The study was reported in the April 2000 issue of the Archives of Pediatric and Adolescent Medicine. Arch Pediatr Adolesc Med 2000 Apr;154(4):375-80

Studying 270 HIV infected and uninfected teenagers, the researchers measured the levels of T lymphocytes, cells that originate in the thymus gland and play important roles in the immune system. Among those cells, they found an unexpectedly higher number of CD8 naive T lymphocytes in adolescents who had been infected with HIV, compared to uninfected adolescents.

Naive T lymphocytes are cells that have not been previously exposed to invading microorganisms, including HIV.

"The high levels of naive CD8 cells that we found suggest that these cells may be capable of mounting an immune response," said the study's lead author, Steven D. Douglas, MD, Children's Hospital, who added, "CD8 cells are major players in killing the virus."

The naive T lymphocytes are produced by the thymus gland, which gradually shrinks after puberty, becoming less active in immune function during adulthood. "If the thymus continues to produce immune system cells in HIV infected adolescents, the adolescent immune system may be stronger than previously thought," said Douglas. "With aggressive use of current medications, we may be able to rebuild immune systems in HIV infected adolescents."

Adolescents represent the fastest growing segment of the U.S. population newly infected with HIV; a 1996 White House report estimated that a new infection occurs every hour of every day. However, because of the long incubation period before symptoms appear, relatively small numbers of HIV infected teenagers are aware of their infection and receiving medical care for it. Another complicating factor is the social situation of many infected adolescents, which may leave them with inadequate access to the healthcare system.

"Although HIV infection has been moving into adolescents, relatively little is known about the specifics of how adolescents' immune system respond to the virus," said Bret Rudy, MD, Children's Hospital, and a co-author of the study.

The current study builds on earlier work by Drs. Douglas and Rudy, who recently published the first reference measurements for cells that act as immune system markers for both HIV infected and healthy adolescents.

The current standard of treatment for controlling HIV infection is called highly active antiretroviral therapy (HAART), a combination of drugs that interfere with the virus' ability to replicate. "Because of their robust immune systems, HIV infected adolescents may be the best candidates to benefit from aggressive drugs such as HAART," said Rudy. "However, it's imperative for individuals to become aware of their infections before they actually become sick, because early treatment may give their immune systems the best opportunity for a strong response."

Rudy is co-chair of Project ACCESS, a social marketing campaign aimed at educating at-risk youth about the importance of HIV counseling and testing.

The current study was co-sponsored by the National Institute of Child Health and Human Development, the U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Drug Abuse, the U.S. National Institute of Mental Health, and the Health Resources and Services Administration.

Blood samples were drawn from adolescents at 16 clinical sites throughout the United States participating in the Adolescent Medicine HIV/AIDS Research Network, established by the U.S. National Institutes of Health and the Health Resources and Services Administration.

Further studies will be conducted on how the immune system of adolescents responds to HIV infection over a period of time.

This article was prepared by AIDS Weekly editors from staff and other reports.

000501
AW000503

Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.